364 related articles for article (PubMed ID: 28960866)
41. Grainyhead-like 2 downstream targets act to suppress epithelial-to-mesenchymal transition during neural tube closure.
Ray HJ; Niswander LA
Development; 2016 Apr; 143(7):1192-204. PubMed ID: 26903501
[TBL] [Abstract][Full Text] [Related]
42. Grainyhead-like 2 Reverses the Metabolic Changes Induced by the Oncogenic Epithelial-Mesenchymal Transition: Effects on Anoikis.
Farris JC; Pifer PM; Zheng L; Gottlieb E; Denvir J; Frisch SM
Mol Cancer Res; 2016 Jun; 14(6):528-38. PubMed ID: 27084311
[TBL] [Abstract][Full Text] [Related]
43. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.
Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y
Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692
[TBL] [Abstract][Full Text] [Related]
44. Upregulated SMAD3 promotes epithelial-mesenchymal transition and predicts poor prognosis in pancreatic ductal adenocarcinoma.
Yamazaki K; Masugi Y; Effendi K; Tsujikawa H; Hiraoka N; Kitago M; Shinoda M; Itano O; Tanabe M; Kitagawa Y; Sakamoto M
Lab Invest; 2014 Jun; 94(6):683-91. PubMed ID: 24709776
[TBL] [Abstract][Full Text] [Related]
45. Grainyhead-like 2 inhibits the coactivator p300, suppressing tubulogenesis and the epithelial-mesenchymal transition.
Pifer PM; Farris JC; Thomas AL; Stoilov P; Denvir J; Smith DM; Frisch SM
Mol Biol Cell; 2016 Aug; 27(15):2479-92. PubMed ID: 27251061
[TBL] [Abstract][Full Text] [Related]
46. The role of GRHL2 and epigenetic remodeling in epithelial-mesenchymal plasticity in ovarian cancer cells.
Chung VY; Tan TZ; Ye J; Huang RL; Lai HC; Kappei D; Wollmann H; Guccione E; Huang RY
Commun Biol; 2019; 2():272. PubMed ID: 31372511
[TBL] [Abstract][Full Text] [Related]
47. Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells.
Du Z; Qin R; Wei C; Wang M; Shi C; Tian R; Peng C
Dig Dis Sci; 2011 Mar; 56(3):741-50. PubMed ID: 20683663
[TBL] [Abstract][Full Text] [Related]
48. Genetic inactivation of Nupr1 acts as a dominant suppressor event in a two-hit model of pancreatic carcinogenesis.
Cano CE; Hamidi T; Garcia MN; Grasso D; Loncle C; Garcia S; Calvo E; Lomberk G; Dusetti N; Bartholin L; Urrutia R; Iovanna JL
Gut; 2014 Jun; 63(6):984-95. PubMed ID: 24026351
[TBL] [Abstract][Full Text] [Related]
49. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
[TBL] [Abstract][Full Text] [Related]
50. Upregulated long noncoding RNA LINC01296 indicates a dismal prognosis for pancreatic ductal adenocarcinoma and promotes cell metastatic properties by affecting EMT.
Yuan Q; Zhang Y; Feng L; Jiang Y
J Cell Biochem; 2019 Jan; 120(1):552-561. PubMed ID: 30203487
[TBL] [Abstract][Full Text] [Related]
51. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
Gordon ER; Wright CA; James M; Cooper SJ
BMC Cancer; 2023 Jun; 23(1):524. PubMed ID: 37291514
[TBL] [Abstract][Full Text] [Related]
52. MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2.
An Y; Cai B; Chen J; Lv N; Yao J; Xue X; Tu M; Tang D; Wei J; Jiang K; Wu J; Li Q; Gao W; Miao Y
Cancer Lett; 2013 Feb; 329(2):228-35. PubMed ID: 23178452
[TBL] [Abstract][Full Text] [Related]
53. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
54. Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer.
Smigiel JM; Parameswaran N; Jackson MW
Mol Cancer Res; 2017 Apr; 15(4):478-488. PubMed ID: 28053127
[TBL] [Abstract][Full Text] [Related]
55. GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification.
Chung VY; Tan TZ; Tan M; Wong MK; Kuay KT; Yang Z; Ye J; Muller J; Koh CM; Guccione E; Thiery JP; Huang RY
Sci Rep; 2016 Feb; 6():19943. PubMed ID: 26887977
[TBL] [Abstract][Full Text] [Related]
56. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
57. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
Yao J; An Y; Wie JS; Ji ZL; Lu ZP; Wu JL; Jiang KR; Chen P; Xu ZK; Miao Y
Swiss Med Wkly; 2011; 141():w13208. PubMed ID: 21630164
[TBL] [Abstract][Full Text] [Related]
58. The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling.
Maity G; Haque I; Ghosh A; Dhar G; Gupta V; Sarkar S; Azeem I; McGregor D; Choudhary A; Campbell DR; Kambhampati S; Banerjee SK; Banerjee S
J Biol Chem; 2018 Mar; 293(12):4334-4349. PubMed ID: 29414775
[TBL] [Abstract][Full Text] [Related]
59. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.
Yang S; He P; Wang J; Schetter A; Tang W; Funamizu N; Yanaga K; Uwagawa T; Satoskar AR; Gaedcke J; Bernhardt M; Ghadimi BM; Gaida MM; Bergmann F; Werner J; Ried T; Hanna N; Alexander HR; Hussain SP
Cancer Res; 2016 Jul; 76(13):3838-50. PubMed ID: 27197190
[TBL] [Abstract][Full Text] [Related]
60. Nestin delineates pancreatic cancer stem cells in metastatic foci of NOD/Shi-scid IL2Rγ(null) (NOG) mice.
Matsuda Y; Yoshimura H; Ueda J; Naito Z; Korc M; Ishiwata T
Am J Pathol; 2014 Mar; 184(3):674-85. PubMed ID: 24412093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
